Novonesis A/S
Novozymes A/S is a Denmark-based biosolutions company that develops industrial enzymes and microbial solutions used to improve performance in manufacturing processes and biological applications. Its products are sold globally across food, agriculture, household care, bioenergy, and other industrial end markets through direct and partner channels.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueProtein-based catalysts sold into food, detergent, feed, and biofuel processes.
Microorganism-based products and fermentation-derived solutions for industrial uses.
Biological inputs and crop-related solutions that support farm productivity.
Formulation support, testing, and customer collaboration around product deployment.
Smaller adjacent biological products and tailored solutions for niche uses.
Customers
Novozymes sells to industrial customers that use enzymes and microbial solutions inside their own production processes, rather than to end consumers. Its customer base includes food and beverage producers, detergent makers, feed manufacturers, bioenergy operators, and agricultural users who value performance, yield, and sustainability benefits.
Buy enzymes for brewing, baking, dairy, and other processing steps to improve yield and consistency.
Buy detergent enzymes and related solutions to improve cleaning performance and formulation efficiency.
Buy enzymes and microbial products that help improve feed conversion and animal performance.
Buy enzymes that support biomass breakdown and conversion in renewable fuel processes.
Buy biological products that support crop health, resilience, and productivity.
Strategy
Novozymes focuses on expanding biosolutions adoption across core industrial end markets by improving customer performance, sustainability, and process efficiency. Its strategy depends on innovation, technical customer support, and a broad market reach that allows it to serve multiple industries and geographies.
Product performance and new applications are central to pricing power and customer retention.
A diversified customer and geography mix reduces dependence on any one end market.
Many customers buy biosolutions to improve resource efficiency and lower environmental impact.
Geography
Novozymes operates globally, with sales spread across developed and emerging markets. The business is exposed to regional demand trends, customer manufacturing footprints, and trade or regulatory conditions in the markets where its products are sold and used.
Risks
Novozymes is exposed to demand cycles in industrial end markets and to customer concentration in large manufacturing accounts that can change volumes quickly. As a biosolutions company, it also faces technology and competitive risks, regulatory scrutiny in agriculture and industrial uses, and foreign-exchange and cross-border operating exposure.
- End-market demand volatilityImpact: HighLikelihood: Medium
Enzyme and microbial sales depend on customer production volumes in food, detergent, feed, and energy markets.
Exposure: Industrial end markets
- Competitive pressure on product performance and pricingImpact: HighLikelihood: Medium
Customers can switch suppliers if another biosolutions provider offers better economics or performance.
Exposure: Core enzyme and microbial portfolios
- Foreign exchange and international operating riskImpact: MediumLikelihood: High
Revenue and costs span multiple currencies and jurisdictions, affecting reported results and execution.
Exposure: Global sales footprint
- Regulatory and compliance riskImpact: MediumLikelihood: Medium
Agricultural and industrial biological products may face approvals, labeling, or usage restrictions.
Exposure: Agriculture and industrial applications
Accounting
Judgemental itemsBusiness combinations can create fair-value adjustments, amortization, and other non-cash charges.
Impact: Affects operating profit and future reported margins
Enzyme and biosolutions businesses often carry meaningful acquired intangible assets.
Impact: Could create material write-downs if assumptions weaken
Specialized biological products may require careful assessment of obsolescence and realizable value.
Impact: Can affect gross profit through write-downs
International sales and supply chains create translation and transaction exposure.
Impact: Affects reported revenue, costs, and equity volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Last updated: 24/10/2026